Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis

@article{Leucht2012AntipsychoticDV,
  title={Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis},
  author={Stefan Leucht and Magdolna Tardy and Katja Komossa and Stephan Heres and Werner Kissling and Georgia Salanti and John M. Davis},
  journal={The Lancet},
  year={2012},
  volume={379},
  pages={2063-2071}
}
BACKGROUND Relapse prevention with antipsychotic drugs compared with placebo in patients with schizophrenia has not been sufficiently addressed by previous systematic reviews. [...] Key MethodWe searched the Cochrane Schizophrenia Group's specialised register for reports published before Nov 11, 2008; and PubMed, Embase, and ClinicalTrials.gov for those before June 8, 2011. We also contacted pharmaceutical companies and searched the reference lists of included studies and previous reviews.Expand
Benefits and harms of antipsychotic drugs in drug-naïve patients with psychosis: A systematic review
  • P.B. Danborg, P.C. Gøtzsche
  • Medicine
  • The International journal of risk & safety in medicine
  • 2019
TLDR
Withdrawal effects in the placebo groups make existing placebo-controlled trials unreliable and the use of antipsychotics cannot be justified based on the evidence the authors currently have. Expand
Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis
TLDR
A network meta-analysis of placebo-controlled and head-to-head randomised controlled trials and compared 32 antipsychotics aimed to compare and rank antipsychotic drugs by quantifying information from randomisedcontrolled trials. Expand
Psychosocial treatments for relapse prevention in schizophrenia: study protocol for a systematic review and network meta-analysis of randomised evidence
TLDR
A network meta-analysis is conducted, integrating direct and indirect comparisons from randomised controlled trials (RCTs) to rank psychosocial treatments for relapse prevention in schizophrenia according to their efficacy, acceptability and tolerability, to obtain a comprehensive ranking of all treatments. Expand
Sixty Years of Placebo-Controlled Antipsychotic Drug Trials in Acute Schizophrenia: Systematic Review, Bayesian Meta-Analysis, and Meta-Regression of Efficacy Predictors.
TLDR
Almost twice as many patients improved with antipsychotics as with placebo, but only a minority experienced a good response, and drug development may benefit from smaller samples but better-selected patients. Expand
Standard versus reduced dose of antipsychotics for relapse prevention in multi-episode schizophrenia: a systematic review and meta-analysis of randomised controlled trials.
TLDR
During maintenance treatment in multi-episode schizophrenia, antipsychotic doses should probably not be reduced below the standard dose range recommended for acute stabilisation, because reducing the dose further is associated with an increased risk of both relapse and all-cause discontinuation. Expand
Factors associated with successful antipsychotic dose reduction in schizophrenia: a systematic review of prospective clinical trials and meta-analysis of randomized controlled trials
TLDR
Clinicians should consider the long-term risk of relapse in younger patients with a relatively short illness duration and keep the final doses higher than CPZE 200 mg/day when reducing antipsychotic doses. Expand
Benefits and harms of antipsychotic drugs in drug-naı̈ve patients with psychosis: A systematic review
OBJECTIVE: To study the benefits and harms of antipsychotics in drug-naı̈ve patients with psychosis. METHODS: This study is a systematic review and meta-analysis of placebo-controlled trials. MainExpand
Long-acting atypical antipsychotics in schizophrenia: A systematic review and meta-analyses of effects on functional outcome
TLDR
Long-acting injectable atypical antipsychotics are beneficial for recovery of psychosocial function in comparison with placebo, but the magnitude of superiority over oral antipsychotic treatment was small. Expand
Definitions of relapse in trials comparing antipsychotic maintenance with discontinuation or reduction for schizophrenia spectrum disorders: A systematic review
TLDR
A systematic review of definitions of relapse in trials of continuous antipsychotic treatment compared with discontinuation, intermittent treatment or dose reduction for people with schizophrenia spectrum disorders found few definitions consistently reflect suggested indications of a clinically significant relapse. Expand
Clozapine and Psychosocial Function in Schizophrenia: A Systematic Review and Meta-Analysis
TLDR
Clozapine does not appear superior to other antipsychotics for improvement of psychosocial function, but both short-term and long-term trials showed beneficial effects on psychossocial function, and only one study explored the predictors of psychOSocial function. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 52 REFERENCES
Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials.
TLDR
Overall, the currently available data suggest that new-generation antipsychotic drugs have the potential to reduce relapse rates. Expand
Maintenance treatment with antipsychotic drugs for schizophrenia.
TLDR
The efficacy of antipsychotic drugs for maintenance treatment in schizophrenia was clear and the results of the primary outcome were robust in a number of subgroup, meta-regression and analyses. Expand
A systematic review of relapse measurement in randomized controlled trials of relapse prevention in first-episode psychosis
TLDR
There is an urgent need for a standardized, universally adopted set of criteria for psychotic relapse with appropriate specification of measurement instruments for use in future RCTs. Expand
Antipsychotic prophylaxis is needed after remission from a first psychotic episode in schizophrenia patients: Results from an aborted randomised trial
TLDR
Discontinuation of antipsychotic medication markedly increases the risk of relapse in stable remitted first-episode schizophrenia patients. Expand
Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study.
TLDR
Aripiprazole, 15 mg once daily, is an effective, well-tolerated treatment for prevention of relapse in patients with chronic, stable schizophrenia. Expand
Zotepine in the prevention of recurrence: a randomised, double-blind, placebo-controlled study for chronic schizophrenia
TLDR
Zotepine is effective in preventing recurrence in patients with chronic schizophrenia, and scores on the BPRS and CGI supported the efficacy of zotEPine. Expand
Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial
TLDR
In a group of asymptomatic patients with first episode psychosis and at least one year of previous antipsychotic drug treatment, maintenance treatment with quetiapine compared with placebo resulted in a substantially lower rate of relapse during the following year. Expand
Prevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: a randomized, placebo-controlled trial in clinically stable patients.
TLDR
Once-daily quetiapine XR (400-800mg/day) was effective in preventing relapse in patients with clinically stable schizophrenia and was well tolerated during longer-term use. Expand
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
TLDR
A meta-analysis of randomised controlled trials to compare the effects of second-generation antipsychotic drugs in patients with schizophrenia provided data for individualised treatment based on efficacy, side-effects, and cost. Expand
A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment.
TLDR
Long-term treatment with asenapine was more effective than placebo in preventing relapse of schizophrenia and appeared to be safe and well tolerated. Expand
...
1
2
3
4
5
...